Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Chronic Lymphocytic Leukemia with Deletion 13q: Prognostic Predictors and Outcome after Treatment with Fludarabine, Cyclophosphamide and Rituximab (FCR)

Abdul Rashid Shah, MD, Tariq Muzzafar, MBBS, Romana Asad, MD, Christine B Peterson, Hagop M. Kantarjian, MD, Alessandra Ferrajoli, MD, William G Wierda, MD PhD, Jan A. Burger, MD PhD, Nitin Jain, MD, Gautam Borthakur, MD, Maliha Khan, MD, Abhishek Chilkulwar, MD, Brion Randolph, MD, Lohith Gowda, MD, Michael J Keating

Blood (2017) 130 (Supplement 1): 5337.

https://doi.org/10.1182/blood.V130.Suppl_1.5337.5337

Published: 2017

Journal Articles

Diagnosing therapy-related acute myeloid leukemia with 8% blasts in bone marrow with concomitant plasma cell myeloma

Beenu Thakral, Tariq Muzzafar

Blood (2017) 130 (2): 231.

https://doi.org/10.1182/blood-2017-04-779751

Published: 2017

Journal Articles

Mutation Analysis in 276 Cases of Newly Diagnosed Acute Myeloid Leukemia By Next Generation Sequencing: Association with Established Prognostic Variables and MRC Risk Groups

Parsa Hodjat, MD, Kankana Ghosh, B. Pharm, Priyanka Priyanka, MPH, Beenu Thakral, MBBS,MD, Keyur P. Patel, MD PhD, Mark Routbort, MD PhD, Rashmi Kanagal-Shamana, MD, C. Cameron Yin, MDPhD, Zhuang Zuo, MD PhD, Raja Luthra, PhD, Tariq Muzzafar, MD

Blood (2015) 126 (23): 1392.

https://doi.org/10.1182/blood.V126.23.1392.1392

Published: 2015

Journal Articles

Gene Expression Profiling for Molecular Features of Response in a Phase I Trial of Alisertib Plus Romidepsin for Relapsed/Refractory Aggressive B- and T-Cell Lymphomas

Blood (2015) 126 (23): 2705.

https://doi.org/10.1182/blood.V126.23.2705.2705

Published: 2015

Journal Articles

Mutation Analysis in 200 Cases of Newly Diagnosed Myelodysplastic Syndrome By Next Generation Sequencing: Association with Established Prognostic Variables and IPSS-R

Kankana Ghosh, B. Pharm, Parsa Hodjat, MD, Priyanka Priyanka, MPH, Beenu Thakral, MBBS,MD, Keyur P. Patel, MD PhD, Mark Routbort, MD PhD, Rashmi Kanagal-Shamana, MD, C. Cameron Yin, MDPhD, Zhuang Zuo, MD PhD, Raja Luthra, PhD, Tariq Muzzafar, MD

Blood (2015) 126 (23): 1703.

https://doi.org/10.1182/blood.V126.23.1703.1703

Published: 2015

Journal Articles

A Phase I Trial of Alisertib Plus Romidepsin for Relapsed/Refractory Aggressive B- and T-Cell Lymphomas

Michelle A. Fanale, MD, Fredrick B. Hagemeister, MD, Luis Fayad, MD, Yasuhiro Oki, MD, Nathan Fowler, MD, Jorge Romaguera, MD, Nina Shah, Hubert Chuang, MD, Lei Feng, MS, Sandra B Horowitz, PharmD, Emily Wesson, APN, Toni Y Hutto, BS, Tariq Muzzafar, MD, Felipe Samaniego, MD, R Eric Davis, MD

Blood (2014) 124 (21): 1744.

https://doi.org/10.1182/blood.V124.21.1744.1744

Published: 2014

Journal Articles

Validation of Alternative Chronic Myelomonocytic Leukemia (CMML)-Specific Prognostic Scoring (CPSS) System in UT MD Anderson Cancer Center Cohort

Priyanka Priyanka, BAMS, Janhavi Raut, BDS, Patricia S Fox, MS, Francesco Stingo, PhD, Tariq Muzzafar, MD

Blood (2014) 124 (21): 3278.

https://doi.org/10.1182/blood.V124.21.3278.3278

Published: 2014

Journal Articles

Plasmablastic Lymphoma: 28 Patient Single Institution Experience

Krina Patel, MD, Lei Feng, M.S., Yasuhiro Oki, MD, Muzaffar Qazilbash, M.D., Tariq Muzzafar, MBBS, Donna M. Weber, M.D., Nathan Fowler, MD, Uday R Popat, MD, Sheeba K. Thomas, M.D., Michelle A. Fanale, MD, Yago Nieto, MD, PhD, Nina Shah, MD, Qaiser Bashir, MD, Fredrick B. Hagemeister, MD, Robert Z. Orlowski, M.D., Ph.D., Jatin J. Shah, M.D.

Blood (2013) 122 (21): 4310.

https://doi.org/10.1182/blood.V122.21.4310.4310

Published: 2013

Journal Articles

Activation of T and NK Cells Following Lenalidomide Therapy in Patients with Follicular Lymphoma.

Seema Rawal, PhD, Nathan Fowler, MD, Min Zhang, Ph.D., Zhiqiang Wang, Ph.D., Tariq Muzzafar, MBBS, Nusrat Harun, MS, Veerabhadran Baladandayuthapani, Ph.D., Rakesh Sharma, Ph.D, David Delgado, Michael Wallace, MD, Carla Heise, PhD, Linda Catherine Lacerte, RN, Felipe Samaniego, M.D., R Eric Davis, M.D, Sattva S. Neelapu, MD

Blood (2012) 120 (21): 2766.

https://doi.org/10.1182/blood.V120.21.2766.2766

Published: 2012

NARROW

Chronic Lymphocytic Leukemia with Deletion 13q: Prognostic Predictors and Outcome after Treatment with Fludarabine, Cyclophosphamide and Rituximab (FCR)

Diagnosing therapy-related acute myeloid leukemia with 8% blasts in bone marrow with concomitant plasma cell myeloma

Mutation Analysis in 276 Cases of Newly Diagnosed Acute Myeloid Leukemia By Next Generation Sequencing: Association with Established Prognostic Variables and MRC Risk Groups

Gene Expression Profiling for Molecular Features of Response in a Phase I Trial of Alisertib Plus Romidepsin for Relapsed/Refractory Aggressive B- and T-Cell Lymphomas

Mutation Analysis in 200 Cases of Newly Diagnosed Myelodysplastic Syndrome By Next Generation Sequencing: Association with Established Prognostic Variables and IPSS-R

A Phase I Trial of Alisertib Plus Romidepsin for Relapsed/Refractory Aggressive B- and T-Cell Lymphomas

Validation of Alternative Chronic Myelomonocytic Leukemia (CMML)-Specific Prognostic Scoring (CPSS) System in UT MD Anderson Cancer Center Cohort

Plasmablastic Lymphoma: 28 Patient Single Institution Experience

Activation of T and NK Cells Following Lenalidomide Therapy in Patients with Follicular Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only